Form 4: Regeneron Pharmaceuticals Director Arthur F. Ryan Reports Stock Sale
SEC Form 4 Filing
Director Arthur F. Ryan of Regeneron Pharmaceuticals, Inc. reported the sale of 1 share of common stock on August 1, 2024, according to a Form 4 filing with the SEC.
Summary
- On August 1, 2024, Arthur F. Ryan, a director of Regeneron Pharmaceuticals, Inc., sold 1 share of common stock at a price of $1,100.03.
- The transaction was executed under a pre-arranged trading plan complying with Rule 10b5-1(c), which was adopted on August 7, 2023.
- Following the reported transaction, Ryan directly owns 17,782 shares of Regeneron common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports a routine stock sale under a pre-arranged trading plan.
Industry Context
Executive stock sales are a common occurrence in publicly traded companies and are often related to personal financial planning rather than a reflection of the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 08/07/2023 | Date of adoption of Rule 10b5-1(c) plan |
| 08/01/2024 | Date of stock sale transaction |
| 08/05/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.